Publicaciones científicas
2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting
J Herrstedt 1 , R Clark-Snow 2 , C H Ruhlmann 3 , A Molassiotis 4 , I Olver 5 , B L Rapoport 6 , M Aapro 7 , K Dennis 8 , P J Hesketh 9 , R M Navari 10 , L Schwartzberg 11 , M L Affronti 12 , M A Garcia-Del-Barrio 13 , A Chan 14 , L Celio 15 , R Chow 16 , M Fleury 17 , R J Gralla 18 , R Giusti 19 , F Jahn 20 , H Iihara 21 , E Maranzano 22 , V Radhakrishnan 23 , M Saito 24 , P Sayegh 25 , S Bosnjak 26 , L Zhang 27 , J Lee 28 , V Ostwal 29 , T Smit 30 , A Zilic 26 , K Jordan 31 , F Scotté 32 ; participants of the MASCC/ESMO Consensus Conference 2022.
Nausea and vomiting are still considered to be two of the most troublesome adverse events (AEs) for patients treated with antineoplastic therapy. To optimise the utility of available antiemetic prophylaxis, updated reviews of the relevant literature and evidence-based guideline recommendations are crucial.
The European Society for Medical Oncology (ESMO) and the Multinational Association of Supportive Care in Cancer (MASCC) completed the fourth Consensus Conference on Antiemetics for the prevention of nausea and vomiting in patients with cancer in Copenhagen in June 2015.1 This article is an update of the 2015 guidelines.
CITA DEL ARTÍCULO ESMO Open. 2024 Feb;9(2):102195. doi: 10.1016/j.esmoop.2023.102195. Epub 2024 Jan 11
Nuestros autores
